Details for Patent: 9,254,278

Which drugs does patent 9,254,278 protect, and when does it expire?

Patent 9,254,278 protects RAVICTI and is included in one NDA.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 9,254,278

Title:	Methods of therapeutic monitoring of nitrogen scavenging drugs
Abstract:	The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Inventor(s):	Scharschmidt; Bruce (San Francisco, CA), Mokhtarani; Masoud (Walnut Creek, CA)
Assignee:	Horizon Therapeutics, Inc. (Deerfield, IL)
Application Number:	14/816,674
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,254,278
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 9,254,278

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Horizon Therap Us	RAVICTI	glycerol phenylbutyrate	LIQUID;ORAL	203284-001	Feb 1, 2013		RX	Yes	Yes						TREATMENT OF A UREA CYCLE DISORDER

International Family Members for US Patent 9,254,278

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012316750
Australia	2017251691
Brazil	112014007357
Canada	2850391
Chile	2014000783